The SURMOUNT-4 trial and what tirzepatide withdrawal really showed

The myth SURMOUNT-4 was designed to correct

A frequent assumption about weight-loss medicines is that they work like a course of antibiotics, take them, finish them, move on. SURMOUNT-4 was set up specifically to test that idea with tirzepatide. In the first phase, all participants received tirzepatide for 36 weeks and achieved meaningful weight reduction, averaging around 20.9% of body weight lost from their starting point. That result alone was striking. Then the trial split: roughly half continued tirzepatide at their established dose; the other half switched to placebo injections, indistinguishable in appearance.

The outcome was unambiguous. Over the following 52 weeks, people who continued tirzepatide lost a further 5.5% of body weight on average, reaching a cumulative reduction of about 25.8% from baseline. Those on placebo regained approximately 14% of body weight during that same period, recovering around two-thirds of what they had previously lost. The trial enrolled 670 adults without type 2 diabetes, all of whom had obesity or overweight alongside at least one weight-related health condition. You can read more about how the wider tirzepatide SURMOUNT programme was structured if you want context on where this trial fits.

So the myth SURMOUNT-4 corrects is this: that the benefits of tirzepatide persist once the medicine stops. The data suggest they largely do not, which is clinically significant information, not a reason to avoid treatment, but a reason to have an honest conversation with a prescriber about duration and goals.

How the trial was designed, and why the design matters here

SURMOUNT-4's two-phase structure is worth understanding because it is what makes the findings so clear. The lead-in phase was open-label, everyone knew they were taking tirzepatide, and doses were titrated from 2.5 mg upward following the standard schedule. This phase lasted 36 weeks, long enough for most participants to reach a stable maintenance dose and achieve substantial weight reduction.

The second phase was double-blind and placebo-controlled. Neither participants nor investigators knew who had switched to placebo, removing the possibility that expectation shaped the result. This matters because weight regain after stopping a medicine can sometimes be attributed to behavioural changes rather than the medicine's absence; the blinded design controls for that. The SURMOUNT-1 trial demonstrated what tirzepatide can achieve in terms of weight loss; SURMOUNT-4 answered the next question: what happens if you stop?

The 52-week withdrawal phase is also long enough to be meaningful. Short-term regain can reflect rebound appetite; regain sustained over a year reflects the underlying physiology. Obesity is a chronic condition influenced by hormonal and metabolic pathways. Tirzepatide works on two of those pathways (GIP and GLP-1 receptors) and when that dual-receptor activity is removed, appetite and energy regulation shift back toward the pre-treatment state. The full tirzepatide clinical overview covers the mechanism in more depth.

What SURMOUNT-4 does not tell us, and what your prescriber weighs up

Trials answer the questions they are powered to answer, and SURMOUNT-4 has boundaries worth knowing. It studied a specific population (adults without type 2 diabetes) over a defined period. It does not tell us whether a planned break followed by restarting produces different outcomes, or how results vary by dose at the point of withdrawal. It also does not address quality-of-life changes or the longer-term cardiovascular effects of the weight regained during the withdrawal phase.

For anyone reading this ahead of a consultation, the practical implication is that duration of treatment is a clinical conversation, not a decision made by a trial result. How long someone takes tirzepatide, when a pause might be considered, and how to plan around life events (treatment timing around planned surgery, for instance, or managing a holiday if the 12 pm order cut-off falls over a bank holiday) are all things a prescriber factors in alongside your individual circumstances. If you are curious about what the average weight-loss percentages across the full SURMOUNT programme look like, those numbers sit in a broader picture of how dose and trial design affect outcomes.

Tirzepatide is available in the UK as Mounjaro, manufactured by Eli Lilly. It holds a UK licence for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition, and NICE recommends it under technology appraisal TA1026 for eligible adults, with specific BMI thresholds for different ethnic backgrounds. For a full summary of the medicine's properties, the NHS tirzepatide information page is the most accessible UK reference.

Why treatment decisions belong with a prescriber, not a trial summary

SURMOUNT-4 is peer-reviewed clinical evidence, but it is not a treatment plan. The finding that weight returns for many people after stopping does not mean treatment must continue indefinitely in every case; it means that question needs a clinical answer rather than an assumption. Some people reach a point where lifestyle changes are well-established and a supervised reduction in treatment is appropriate. Others have comorbidities where sustained weight loss carries clear ongoing benefit. Those distinctions are exactly what an independent prescriber is trained to make.

At nume, every consultation is read by a GPhC-registered prescriber (a person, not automated triage) who reviews your health background before any prescription is issued. Repeat orders go through the same clinical review process; there are no automatic renewals. If you are thinking about whether tirzepatide, sold in the UK as Mounjaro, might be appropriate for you, the right next step is a clinical assessment rather than a trial result. If you would like to understand the broader cost picture before starting, the Mounjaro cost page sets out what private treatment typically involves in the UK.

You can start your free consultation with our prescribers at any point.